Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neuroblastoma × Influenza Vaccines × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neuroblastoma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Ganglioneuroblastoma 1

Interventions

Temozolomide 10 Irinotecan 8 Cyclophosphamide 7 dinutuximab 5 aldesleukin 4 Interleukin-2 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 sargramostim 3 fludarabine 3 Topotecan 3 Melphalan 3 Isotretinoin 3 Filgrastim 3 gallium Ga 68 dotatate 2 Vincristine 2 TPI-287 2 Peripheral Blood Stem Cell Transplantation 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Carboplatin 2 venetoclax 1 trametinib 1 thymoglobulin 1 talazoparib 1 sonidegib 1 silmitasertib 1 plerixafor 1 olaparib 1 naxitamab 1 lutetium Lu 177 dotatate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡